Systemic sclerosis & Raynaud's
A Multinational Survey Investigating the Unmet Needs and Patient Perspectives Concerning Proton Pump Inhibitors in Systemic Sclerosis
Authors' conclusion
Despite the frequent use of PPIs in patients with SSc, there is significant heterogeneity in prescription, and combination therapy (PPIs plus other medication for acid reflux) is not uncommon (approximately 40%).
Study context
- Population
- Systemic Sclerosis (SSc) patients treated with proton pump inhibitors (PPIs), invited through international patient associations and social media
- Participants
- 301 patients14 countries
- Outcome
- Problems/complaints and unmet needs of SSc patients on PPIs
Methodological detailsonline survey, multinational
- Online survey
- Multinational
Main finding
As reported in the abstract
- Multiple PPIs use: two in series
- 30%
- Multiple PPIs use: three in series
- 21%
- Improvement in gastrointestinal symptoms from PPIs
- 89%
- Potentially concerned about side effects
- 79%
- Received lifestyle information
- 58%
- Searched online for information about PPIs
- 85%
- Surgical approach discussed
- 12%
- Willing to undergo surgery to resolve gastroesophageal reflux disease (GERD) symptoms (but had important concerns)
- 46%
Observational data: associations, not effects.
Safety
- Side effects attributed to PPIs (uncommon)
- 19%
Original publication
A Multinational Survey Investigating the Unmet Needs and Patient Perspectives Concerning Proton Pump Inhibitors in Systemic Sclerosis. Arthritis Care Res (Hoboken). Published 29 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →